Isis Pharmaceuticals Earns $3.0 Million from GSK
CARLSBAD, Calif., May 15, 2014
CARLSBAD, Calif., May 15, 2014 /PRNewswire/ -- Isis Pharmaceuticals, Inc.
(NASDAQ: ISIS) announced today that it has earned a $3.0 million milestone
payment from GlaxoSmithKline (GSK) related to the initiation of a natural
history study, which will support the advancement of one of the alliance
Isis Pharmaceuticals, Inc.
"We have had a very productive alliance with GlaxoSmithKline, from which we
have advanced three antisense drugs in our pipeline, including ISIS-TTR[Rx],
which is currently in Phase 3 development. The payment we earned today is
further evidence of this productive collaboration," said B. Lynne Parshall,
chief operating officer at Isis.
GlaxoSmithKline and Isis have established an alliance focused on leveraging
antisense technology to develop drugs to treat rare and infectious diseases.
This alliance provides GlaxoSmithKline with access to Isis' expertise in drug
discovery and development of RNA-targeted therapeutics, with Isis retaining
responsibility for the discovery and development of compounds to the alliance
targets from inception to proof-of-concept. Current development-stage
programs include ISIS-TTR[Rx] for patients with familial transthyretin
polyneuropathy, ISIS-HBV[Rx] for patients with hepatitis B virus and
ISIS-GSK4[Rx] for patients with an undisclosed ocular disorder.
ABOUT ISIS PHARMACEUTICALS, INC.
Isis is exploiting its leadership position in antisense technology to discover
and develop novel drugs for its product pipeline and for its partners. Isis'
broad pipeline consists of 32 drugs to treat a wide variety of diseases with
an emphasis on cardiovascular, metabolic, severe and rare diseases, including
neurological disorders, and cancer. Isis' partner, Genzyme, is
commercializing Isis' lead product, KYNAMRO^®, in the United States and other
countries for the treatment of patients with homozygous FH. Isis' patents
provide strong and extensive protection for its drugs and technology.
Additional information about Isis is available at www.isispharm.com.
ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT
This press release includes forward-looking statements regarding Isis'
strategic alliance with GSK, and the discovery, development, activity,
therapeutic and commercial potential and safety of drugs developed from the
alliance. Any statement describing Isis' goals, expectations, financial or
other projections, intentions or beliefs is a forward-looking statement and
should be considered an at-risk statement. Such statements are subject to
certain risks and uncertainties, particularly those inherent in the process of
discovering, developing and commercializing drugs that are safe and effective
for use as human therapeutics, and in the endeavor of building a business
around such drugs. Isis' forward-looking statements also involve assumptions
that, if they never materialize or prove correct, could cause its results to
differ materially from those expressed or implied by such forward-looking
statements. Although Isis' forward-looking statements reflect the good faith
judgment of its management, these statements are based only on facts and
factors currently known by Isis. As a result, you are cautioned not to rely
on these forward-looking statements. These and other risks concerning Isis'
programs are described in additional detail in Isis' annual report on Form
10-K for the year ended December 31, 2013, and its most recent quarterly
report on Form 10-Q, which are on file with the SEC. Copies of these and other
documents are available from the Company.
In this press release, unless the context requires otherwise, "Isis,"
"Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its
Isis Pharmaceuticals^® is a registered trademark of Isis Pharmaceuticals,
Inc. KYNAMRO^® is a registered trademark of Genzyme Corporation.
Logo - http://photos.prnewswire.com/prnh/20130807/LA60006LOGO
SOURCE Isis Pharmaceuticals, Inc.
Contact: D. Wade Walke, Ph.D., Vice President, Corporate Communications and
Investor Relations, 760-603-2741 or Amy Blackley, Ph.D., Associate Director,
Corporate Communications, 760-603-2772
Press spacebar to pause and continue. Press esc to stop.